Improving atopic eczema care through international collaboration In a major matter, no details are small

Atopic eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition with increasing global prevalence. Characterized by pruritic, eczematous lesions, its severity ranges from mild to severe. Most cases are mild and can be managed with trigger avoidance, emollients, and topical anti-inflammatory treatments. For patients unresponsive to these treatments, options such as phototherapy or systemic immunomodulatory drugs may be necessary. However, significant gaps remain in understanding the long-term safety, efficacy, and cost-effectiveness of these treatments, particularly across diverse patient populations.
This thesis aims to address these gaps by improving the care of atopic eczema through international collaboration. It focuses on several key areas. First, it reviews the evidence regarding the diagnostic accuracy of diagnostic criteria for atopic eczema, aiming to standardize diagnostic practices, which would enhance study comparability and consistency. Second, it evaluates the effectiveness and safety of phototherapy as a treatment, providing a critical assessment of existing research. Third, this thesis highlights the significance of international collaboration in standardizing real-world data collection through the TREatment of ATopic eczema (TREAT) Registry Taskforce, with a focus on improving and assessing standardization and cooperation. Finally, it examines the safety of various systemic treatments for atopic eczema using real-world data, including during the COVID-19 pandemic.
Focusing on every detail, from accurate diagnosis and data collection techniques to robust safety monitoring, will pave the way for improved health outcomes and more effective treatments for atopic eczema, ultimately enhancing its management and care.